Wave Life Sciences LTD Schedule 13G passive stakes

Adage Capital Management, L.P. and its principals have reported beneficial ownership of 1,000,000 ordinary shares in Wave Life Sciences Ltd., representing 0.53% of the outstanding class.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G, reporting beneficial ownership of 5,192,761.43 shares of Wave Life Sciences common stock, representing 2.8% of the class.

Adage Capital Management and its principals report a 5.35% beneficial ownership stake in Wave Life Sciences Ltd. as of December 31, 2025.

FMR LLC and its affiliates, including Abigail P. Johnson, reported beneficial ownership of 8.5% of Wave Life Sciences Ltd.'s common stock as of December 31, 2025.

Adage Capital Management, L.P. and its principals report a 9.65% beneficial ownership stake in Wave Life Sciences Ltd. as of June 30, 2025.

Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, has reported a beneficial ownership of 8.15% in Wave Life Sciences Ltd., totaling 12,516,500 ordinary shares.

Maverick Capital, along with its affiliates, has disclosed a 5.4% beneficial ownership stake in Wave Life Sciences Ltd., holding 8,261,242 ordinary shares as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.1% beneficial ownership stake in Wave Life Sciences Ltd. as of December 31, 2024.